HR + /HER2-low breast cancer is a significant subgroup of conventional HR + /HER2-negative breast cancer, and combination of CDK4/6 inhibitor and endocrine therapy is the standard first-line and second-line treatments for advanced HR + /HER2-low breast cancer. Nevertheless, it remains ...
HER2 mRNA expression. Strikingly, neratinib reversed the efficacy of CDK4/6 inhibitor and endocrine therapy by reducing HER2 mRNA stability in HR+/HER2-low breast cancer through the interaction of HER2 3’-UTR region with hsa-miR-23a-5p. Even after reducing neratinib dosage to the standard 1/...
用75%酒精消毒冻存管外壁,在无菌操作台内打开冻存管。 将ZR-75-30细胞悬液转移至含10 ml预热完全培养基的离心管中,以1000 rpm离心5分钟。 弃去上清,加入1 ml预热完全培养基重悬ZR-75-30细胞。 将细胞悬液转移至T25培养瓶中,加入适量完全培养基,置于37°C、5% CO2培养箱中培养ZR-75-30细胞。 传代培养 ...
包装1瓶 最小起订量1瓶 发货地上海 更新日期2025-03-13 QQ交谈微信洽谈 产品详情 中文名称:人乳腺癌细胞(非三阴)zr751/LUC(带荧光素酶)英文名称:zr751/LUC 品牌:晶风生物产地:上海 保存条件:常温/液氮产品类别:ATCC细胞 ATCC细胞系 货号:GT1347LUC用途范围:细胞培养 ...
The responsiveness of the cells to knockdown of AKT was not affected by mutational status of p53 but appeared correlated with overexpression of HER2. To ... S Koseoglu,Z Lu,C Kumar,... - 《Cancer Biology & Therapy》 被引量: 172发表: 2007年 Cyclin D1, Id1 and EMT in breast cancer ...
1、年龄至少为18岁至75岁(含两端值),男女不限。 2、筛选时体重指数(BMI)介于20-40kg/m^2(含)之间。 3、确诊2型糖尿病时间≥6个月。 4、A部分入选标准: ①接受至多3种口服降糖药,口服降糖药在随机前保持剂量稳定≥3个月。口服降糖药必须包括二甲双胍(要求筛选前二甲双胍用量≥1.5...
In PDAC, HER3 is the preferred dimerization partner of EGFR15 with its concomitant activation rendering this malignancy impervious to EGFR and HER2 targeted therapy5. Furthermore, EGFR and HER3 are highly expressed in PDAC, marking this aggressive disease with poor survival rates5,6. With this ...
C. et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586–592 (2010). Article CAS PubMed Google Scholar Gaykema, S. B. et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate ...
segregation Iftasishwioonrtwhitmhetnhteioanbisnegncthe aotftahgegMlomgHer2agtreasinors aggregated grains, as displayed in Fig. 3(e). The NBDP (Fig. 3(f)) corresponding to the white circular lable shown cinamFIinegf.o r3or(dmee)rnstahonooiwncsvreyhssattliaogll-aidtneieftfγrha...